Phospho-LRP6 (Ser1490)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产物编号xy- 3253R
英文名称Phospho-LRP6 (Ser1490)
中文名称磷酸化低密度脂蛋白受体相关蛋白6抗体
别 名LRP6 (Phospho-Ser1490); LRP6 (Phospho-S1490); p-LRP6 (Ser1490); LRP6 (phospho S1490); p-LRP6 (phospho S1490);p-LRP6 (S1490); ADCAD2; C030016K15Rik; Cd; FLJ90062; FLJ90421; Low density lipoprotein receptor related protein 6; LRP6_HUMAN; Low-density lipoprotein receptor-related protein 6; low-density lipoprotein receptor-related protein 6 precursor; LRP-6.
JournalPMIDIFApplicationJournal of Cellular and Molecular Medicine (2014)244475934.7530IFLaboratory Investigation (2016)266584533.6760IHC-P
说 明 书100ul
产物类型磷酸化抗体
研究领域肿瘤 **学 信号转导 转录调节因子 合成与降解
抗体来源搁补产产颈迟
克隆类型笔辞濒测肠濒辞苍补濒
Phospho-LRP6 (Ser1490)抗体交叉反应 Human, Mouse, Rat, Chicken, Dog, Pig, Cow, Horse,
产物应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量175kDa
细胞定位细胞浆 细胞膜
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated synthesised phosphopeptide derived from human LRP6 around the phosphorylation site of Ser1490:P(p-S)PA
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Phospho-LRP6 (Ser1490)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产物介绍产补肠办驳谤辞耻苍诲:
This gene encodes a member of the low density lipoprotein (LDL) receptor gene family. LDL receptors are transmembrane cell surface proteins involved in receptor-mediated endocytosis of lipoprotein and protein ligands. The protein encoded by this gene functions as a receptor or, with Frizzled, a co-receptor for Wnt and thereby transmits the canonical Wnt/beta-catenin signaling cascade. Through its interaction with the Wnt/beta-catenin signaling cascade this gene plays a role in the regulation of cell differentiation, proliferation, and migration and the development of many cancer types. This protein undergoes gamma-secretase dependent RIP- (regulated intramembrane proteolysis) processing but the precise locations of the cleavage sites have not been determined.[provided by RefSeq, Dec 2009].
Function:
Component of the Wnt-Fzd-LRP5-LRP6 complex that triggers beta-catenin signaling through inducing aggregation of receptor-ligand complexes into ribosome-sized signalsomes. Cell-surface coreceptor of Wnt/beta-catenin signaling, which plays a pivotal role in bone formation. The Wnt-induced Fzd/LRP6 coreceptor complex recruits DVL1 polymers to the plasma membrane which, in turn, recruits the AXIN1/GSK3B-complex to the cell surface promoting the formation of signalsomes and inhibiting AXIN1/GSK3-mediated phosphorylation and destruction of beta-catenin. Required for posterior patterning of the epiblast during gastrulation.
Subunit:
Homodimer; disulfide-linked. Forms phosphorylated oligomer aggregates on Wnt-signaling. Forms a WNT-signaling complex formed of a WNT protein, a FZD protein and LRP5 or LRP6. Interacts (via the extracellular domain) with WNT1; the interaction is enhanced by prior formation of the Wnt/Fzd complex. Interacts (via the beta-propeller regions 3 and 4) with WNT3A. Interacts (via the beta-propeller regions 1 and 2) with WNT9B. Interacts with FZD5; the interaction forms a coreceptor complex for Wnt signaling and is inhibited by DKK1 and C1orf187. Interacts (via beta propeller regions 3 and 4) with DKK1; the interaction inhibits FZD5/LRP6 complex formation. Interacts with DKK2. Interacts with C1orf187/DRAXIN; the interaction inhibits Wnt signaling. Interacts (via the phosphorylated PPPSP motifs) with AXIN1; the interaction recruits the AXIN1/GSK3B complex to cell surface LRP6 signalsomes. Interacts with GRB10; the interaction prevents AXIN1 binding, thus negatively regulating the Wnt signaling pathway. Interacts (via the extracellular domain) with RSPO1; the interaction activates Wnt/beta-catenin signaling. Interacts (via the extracellular domain) with RSPO3 (via the cysteine rich domain); the interaction activates Wnt/beta-catenin signaling. Interacts (via the beta-propeller regions 1 and 2) with SOST; the interaction competes with DKK1 for binding for inhibiting beta-catenin signaling. Interacts with MESD; the interaction prevents the formation of LRP6 aggregates and targets LRP6 to the plasma membrane. Interacts (via the cytoplasmic domain) with CSNKIE; the interaction phosphorylates LRP6, binds AXIN1 and inhibits AXIN1/GSK3B-mediated phosphorylation of beta-catenin. Interacts with MACF1.
Subcellular Location:
Membrane; Single-pass type I membrane protein. Endoplasmic reticulum. Note=On Wnt signaling, undergoes a cycle of caveolin- or clathrin-mediated endocytosis and plasma membrane location. Released from the endoplasmic reticulum on palmitoylation. Mono-ubiquitination retains it in the endoplasmic reticulum in the absence of palmitoylation. On Wnt signaling, phosphorylated, aggregates and colocalizes with AXIN1 and GSK3B at the plasma membrane in LRP6-signalsomes. Chaperoned to the plasma membrane by MESD.
Tissue Specificity:
Widely co-expressed with LRP5 during embryogenesis and in tissues.
Post-translational modifications:
Dual phosphorylation of cytoplasmic PPPSP motifs sequentially by GSK3 and CK1 is required for AXIN1-binding, and subsequent stabilization and activation of beta-catenin via preventing GSK3-mediated phosphorylation of beta-catenin. Phosphorylated, in vitro, by GRK5/6 within and outside the PPPSP motifs. Phosphorylation at Ser-1490 by CDK14 during G2/M phase leads to regulation of the Wnt signaling pathway during the cell cycle. Phosphorylation by GSK3B is induced by RPSO1 binding and inhibited by DKK1. Phosphorylated, in vitro, by casein kinase I on Thr-1479.
Undergoes gamma-secretase-dependent regulated intramembrane proteolysis (RIP). The extracellular domain is first released by shedding, and then, through the action of gamma-secretase, the intracellular domain (ICD) is released into the cytoplasm where it is free to bind to GSK3B and to activate canonical Wnt signaling.
Palmitoylation on the two sites near the transmembrane domain leads to release of LRP6 from the endoplasmic reticulum.
Mono-ubiquitinated which retains LRP6 in the endoplasmic reticulum.
N-glycosylation is required for cell surface location.
DISEASE:
Defects in LRP6 are the cause of autosomal dominant coronary artery disease type 2 (ADCAD2) [MIM:610947].
Similarity:
Belongs to the LDLR family.
Contains 4 EGF-like domains.
Contains 3 LDL-receptor class A domains.
Contains 20 LDL-receptor class B repeats.
SWISS:
O75581
Gene ID:
4040
Phospho-LRP6 (Ser1490)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“驰”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
Phospho-LRP6 (Ser1490)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
滨驳骋经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 CCR-1/CD191 细胞表面趋化因子受体1抗体
合格 phospho-ATM (Tyr170) 磷酸化****扩张性共济失调症突变蛋白抗体
合格 KCNQ2 钾离子通道蛋白家族KCNQ2抗体
合格 NPC2 尼曼匹克C2前体蛋白抗体
合格 TNFRSF18 糖皮质**诱导肿瘤坏死因子受体抗体
合格 ELAVL2 + ELAVL4 ELAVL2+ELAVL4蛋白抗体
合格 Engrailed 1 同源盒蛋白转录因子EN1抗体
合格 合格 PPP2R2B/PP2A-B55 蛋白质磷酸酶2A-B55抗体
合格 合格 REEP1 受体辅助蛋白1抗体
合格 SHBG 性**结合球蛋白抗体
合格 SPG48 SPG48蛋白抗体
合格 SPG7 痉挛性截瘫蛋白7/基质细胞粘附调节蛋白抗体
合格 SULT4A1 脑磺基转移酶样蛋白4A1抗体
合格 OPA1 视神经萎缩相关蛋白1抗体
合格 TATA binding protein TBP/TBP TATA结合蛋白TBP/TFIID抗体
合格 合格 TDRD3 Tudor结构域蛋白TDRD3抗体
合格 合格 TMEM158 跨膜蛋白158抗体
合格 WRB 色氨酸丰富蛋白抗体
合格 ZFYVE27 锌指FYVE结构域蛋白27抗体
合格 GBA β-葡萄糖脑苷脂酶抗体
合格 IF3 线粒体翻译起始因子3抗体
合格 PAR-2 蛋白酶激活受体-2抗体
合格 ATBF1 α增强子结合蛋白1抗体
合格 RhoA RhoA抗体
合格 BRSK2 脑蛋白丝氨酸/苏氨酸激酶29抗体
合格 CCM2 脑海绵状血管畸形蛋白2抗体
合格 CRMP3 二氢嘧啶酶相关蛋白3抗体
合格 DCDC2 双皮层蛋白结构域蛋白DCDC2抗体
合格 Emx1 有脊椎动物脑发育相关蛋白Emx1抗体
合格 FNBP1L FNBP1L蛋白抗体
合格 合格 合格 GPM6B 神经细胞膜糖蛋白M6b
合格 GPR56 蛋白偶联受体56抗体